Therapeutic Indications

Cabozantinib is indicated for:

Hepatocellular Carcinoma (HCC)

Irrespective of gender only Adults (18 years old or older)

Cabozantinib is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 60 mg once daily

Renal Cell Carcinoma (RCC)

Irrespective of gender only Adults (18 years old or older)

Cabozantinib is indicated for the treatment of advanced renal cell carcinoma (RCC):

  • in treatment-na├»ve adults with intermediate or poor risk
  • in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 60 mg once daily